Randomisierte Studie zur Wirksamkeit von FOLFIRI in Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen Karzinoms English translation: Randomised study for efficiency of FOLFIRI in combination with Cetuximab vs. Bevacizumab in first-line-therap

Primary objectives: Comparative validation of antitumor efficacy measured by objective remissionrate defined by RECIST-criteria (OR= CR+ PR), assessed within intent-to-treat-collective.
Primary endpoints: Progression of metastatic colorectal cancer or patient’s death

核心研究目标：在意向治疗人群（Intent-to-Treat population）中，对比验证由实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumors，RECIST）定义的客观缓解率（Objective Response Rate，OR=完全缓解（Complete Response，CR）+部分缓解（Partial Response，PR））所衡量的抗肿瘤疗效。
主要研究终点：转移性结直肠癌进展或患者死亡